Press centre

Thailand Activates First Site in Global Phase 3 Clinical Study of Zoliflodacin as a New Gonorrhoea Treatment
26 Mar 2021

Thailand Activates First Site in Global Phase 3 Clinical Study of Zoliflodacin as a New Gonorrhoea Treatment

GARDP and Entasis Therapeutics announced today the activation of the first site in Thailand as part of a global phase 3 clinical study of zoliflodacin for the treatment of gonorrhoea.

Read more

Media contacts

For media inquiries, please contact the GARDP Communications Department:

Phone: +41 22 555 19 90 | Email: communications@gardp.org

We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.